417 Design and rationale of a phase 1 study evaluating AMG 256, a novel, targeted, IL-21 receptor agonist and anti-PD-1 antibody, in patients with advanced solid tumors
| dc.contributor.author | Durm, Gregory | |
| dc.contributor.author | Frentzas, Sophia | |
| dc.contributor.author | Rasmussen, Erik | |
| dc.contributor.author | Najmi, Saltanat | |
| dc.contributor.author | Sadraei, Nooshin | |
| dc.contributor.department | Medicine, School of Medicine | en_US |
| dc.date.accessioned | 2022-02-08T21:16:11Z | |
| dc.date.available | 2022-02-08T21:16:11Z | |
| dc.date.issued | 2020-11 | |
| dc.eprint.version | Final published version | en_US |
| dc.identifier.citation | Durm, G., Frentzas, S., Rasmussen, E., Najmi, S., & Sadraei, N. (2020). 417 Design and rationale of a phase 1 study evaluating AMG 256, a novel, targeted, IL-21 receptor agonist and anti-PD-1 antibody, in patients with advanced solid tumors. Journal for ImmunoTherapy of Cancer, 8(Suppl 3). https://doi.org/10.1136/jitc-2020-SITC2020.0417 | en_US |
| dc.identifier.uri | https://hdl.handle.net/1805/27720 | |
| dc.language.iso | en | en_US |
| dc.publisher | BMJ | en_US |
| dc.relation.isversionof | 10.1136/jitc-2020-SITC2020.0417 | en_US |
| dc.relation.journal | Journal for ImmunoTherapy of Cancer | en_US |
| dc.rights | Attribution-NonCommercial 4.0 International | |
| dc.rights.uri | https://creativecommons.org/licenses/by-nc/4.0 | * |
| dc.source | Publisher | en_US |
| dc.subject | advanced solid tumors | en_US |
| dc.subject | AMG 256 monotherapy | en_US |
| dc.subject | phase 1 study | en_US |
| dc.title | 417 Design and rationale of a phase 1 study evaluating AMG 256, a novel, targeted, IL-21 receptor agonist and anti-PD-1 antibody, in patients with advanced solid tumors | en_US |
| dc.type | Article | en_US |